Canadian Association of Gastroenterology Position Statement: Hip Fracture and Proton Pump Inhibitor Therapy-a 2013 Update

Overview

Journal Can J Gastroenterol

Specialty Gastroenterology

Date 2013 Nov 20

PMID 24251323

Citations 4

Authors

Paul Moayyedi

Yuhong Yuan

Grigorios Leontiadis

Affiliations

Soon will be listed here.

Citing Articles

ACG and CAG Clinical Guideline: Management of Dyspepsia.

Moayyedi P, Lacy B, Andrews C, Enns R, Howden C, Vakil N Am J Gastroenterol. 2017; 112(7):988-1013.

PMID: 28631728 DOI: 10.1038/ajg.2017.154.

Cost Effectiveness of Gastroprotection with Proton Pump Inhibitors in Older Low-Dose Acetylsalicylic Acid Users in the Netherlands.

Chau S, Sluiter R, Kievit W, Wensing M, Teichert M, Hugtenburg J Drugs Aging. 2017; 34(5):375-386.

PMID: 28361278 PMC: 5408060. DOI: 10.1007/s40266-017-0447-9.

Proton pump inhibitors and risk of bone fractures.

Leontiadis G, Moayyedi P Curr Treat Options Gastroenterol. 2014; 12(4):414-23.

PMID: 25209137 DOI: 10.1007/s11938-014-0030-y.

A benefit-risk assessment of the use of proton pump inhibitors in the elderly.

Masclee G, Sturkenboom M, Kuipers E Drugs Aging. 2014; 31(4):263-82.

PMID: 24634248 DOI: 10.1007/s40266-014-0166-4.

References

Roux C, Goldstein J, Zhou X, Klemes A, Lindsay R . Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors. Osteoporos Int. 2011; 23(1):277-84. DOI: 10.1007/s00198-011-1574-5. View

Yong M, Elliott J, Woolley I, Hoy J . Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients. J Acquir Immune Defic Syndr. 2011; 57(3):205-10. DOI: 10.1097/QAI.0b013e31821ecf4c. View

Moayyedi P, Cranney A . Hip fracture and proton pump inhibitor therapy: balancing the evidence for benefit and harm. Am J Gastroenterol. 2008; 103(10):2428-31. DOI: 10.1111/j.1572-0241.2008.02031.x. View

Gage B, Birman-Deych E, Radford M, Nilasena D, Binder E . Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch Intern Med. 2006; 166(2):241-6. DOI: 10.1001/archinte.166.2.241. View

Targownik L, Lix L, Leung S, Leslie W . Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2009; 138(3):896-904. DOI: 10.1053/j.gastro.2009.11.014. View

Womack J, Goulet J, Gibert C, Brandt C, Chang C, Gulanski B . Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One. 2011; 6(2):e17217. PMC: 3040233. DOI: 10.1371/journal.pone.0017217. View

Gray S, LaCroix A, Larson J, Robbins J, Cauley J, Manson J . Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med. 2010; 170(9):765-71. PMC: 4240017. DOI: 10.1001/archinternmed.2010.94. View

Mello M, Weideman R, Little B, Weideman M, Cryer B, Brown G . Proton pump inhibitors increase the incidence of bone fractures in hepatitis C patients. Dig Dis Sci. 2012; 57(9):2416-22. DOI: 10.1007/s10620-012-2185-5. View

de Vries F, Cooper A, Cockle S, van Staa T, Cooper C . Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 2009; 20(12):1989-98. DOI: 10.1007/s00198-009-0891-4. View

10.

Targownik L, Lix L, Metge C, Prior H, Leung S, Leslie W . Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008; 179(4):319-26. PMC: 2492962. DOI: 10.1503/cmaj.071330. View

11.

Yu E, Blackwell T, Ensrud K, Hillier T, Lane N, Orwoll E . Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008; 83(4):251-9. PMC: 2596870. DOI: 10.1007/s00223-008-9170-1. View

12.

Abrahamsen B, Eiken P, Eastell R . Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med. 2011; 171(11):998-1004. DOI: 10.1001/archinternmed.2011.20. View

13.

Vestergaard P, Rejnmark L, Mosekilde L . Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006; 79(2):76-83. DOI: 10.1007/s00223-006-0021-7. View

14.

Kaye J, Jick H . Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008; 28(8):951-9. DOI: 10.1592/phco.28.8.951. View

15.

Pouwels S, Lalmohamed A, Souverein P, Cooper C, Veldt B, Leufkens H . Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 2010; 22(3):903-10. PMC: 3034906. DOI: 10.1007/s00198-010-1337-8. View

16.

Feldstein A, Weycker D, Nichols G, Oster G, Rosales G, Boardman D . Effectiveness of bisphosphonate therapy in a community setting. Bone. 2008; 44(1):153-9. DOI: 10.1016/j.bone.2008.09.006. View

17.

Hill A . THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION?. Proc R Soc Med. 1965; 58:295-300. PMC: 1898525. DOI: 10.1177/003591576505800503. View

18.

Turner M, Camacho X, Fischer H, Austin P, Anderson G, Rochon P . Levothyroxine dose and risk of fractures in older adults: nested case-control study. BMJ. 2011; 342:d2238. PMC: 3084377. DOI: 10.1136/bmj.d2238. View

19.

Chiang C, Liu C, Chen P, Huang C, Hsu C, Chen Z . Hip fracture and risk of acute myocardial infarction: a nationwide study. J Bone Miner Res. 2012; 28(2):404-11. DOI: 10.1002/jbmr.1714. View

20.

Khalili H, Huang E, Jacobson B, Camargo Jr C, Feskanich D, Chan A . Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ. 2012; 344:e372. PMC: 3269660. DOI: 10.1136/bmj.e372. View